Literature DB >> 33482868

Obesity, leptin, and deregulation of microRNA in lipid metabolisms: their contribution to breast cancer prognosis.

Kartika W Taroeno-Hariadi1, Mardiah S Hardianti2, Hemi Sinorita3, Teguh Aryandono4.   

Abstract

Obesity and Metabolic Syndrome have been associated with cardiovascular, diabetes and cancer incidence. Obesity is a state of inflammation. There are cross-talks between adipocyte, adipokines, pro-inflammatory cytokines, insulin, leptin, and other growth factors to initiate signals for proliferation, anti-apoptosis, and angiogenesis. Those networks lead to cancer initiation, promotion, progression, and metastasis. Post menopause women with breast cancer commonly have overweight, obesity, and metabolic syndrome, which are previously reported as conditions to be associated with breast cancer prognosis. MicroRNAs (miRNAs), small non-coding RNA that regulate gene expression, are known to play important roles either in metabolic or carcinogenesis process in patients with breast cancer. Some miRNAs expressions are deregulated in persons either with obesity, breast cancer, or breast cancer with co-morbid obesity. This literature review aimed at reviewing recent publications on the role of obesity, leptin, and microRNA deregulation in adverse prognosis of breast cancer. Understanding the influence of deregulated miRNAs and their target genes in patients with breast cancer and obesity will direct more studies to explore the potential prognostic role of obesity in breast cancer from epigenetic points of view.

Entities:  

Keywords:  Breast cancer; Lipid metabolism; Obesity; Prognosis; microRNA

Year:  2021        PMID: 33482868     DOI: 10.1186/s13098-020-00621-4

Source DB:  PubMed          Journal:  Diabetol Metab Syndr        ISSN: 1758-5996            Impact factor:   3.320


  72 in total

1.  Risk of metabolic syndrome in postmenopausal breast cancer survivors.

Authors:  Daniel de Araújo Brito Buttros; Eliana Aguiar Petri Nahas; Heloísa De Luca Vespoli; Gilberto Uemura; Bruno da Rosa de Almeida; Jorge Nahas-Neto
Journal:  Menopause       Date:  2013-04       Impact factor: 2.953

Review 2.  Adipocyte-Tumor Cell Metabolic Crosstalk in Breast Cancer.

Authors:  Andrew J Hoy; Seher Balaban; Darren N Saunders
Journal:  Trends Mol Med       Date:  2017-03-19       Impact factor: 11.951

3.  Metabolic Obesity Phenotypes and Risk of Breast Cancer in Postmenopausal Women.

Authors:  Geoffrey C Kabat; Mimi Y Kim; Jennifer S Lee; Gloria Y Ho; Scott B Going; Jennifer Beebe-Dimmer; JoAnn E Manson; Rowan T Chlebowski; Thomas E Rohan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-09-22       Impact factor: 4.254

4.  Breast cancer risk in metabolically healthy but overweight postmenopausal women.

Authors:  Marc J Gunter; Xianhong Xie; Xiaonan Xue; Geoffrey C Kabat; Thomas E Rohan; Sylvia Wassertheil-Smoller; Gloria Y F Ho; Judith Wylie-Rosett; Theresa Greco; Herbert Yu; Jeannette Beasley; Howard D Strickler
Journal:  Cancer Res       Date:  2015-01-15       Impact factor: 12.701

Review 5.  A summary for molecular regulations of miRNAs in breast cancer.

Authors:  Shaymaa M M Yahya; Ghada H Elsayed
Journal:  Clin Biochem       Date:  2014-12-23       Impact factor: 3.281

6.  Metabolic syndrome, obesity, and the risk of cancer development.

Authors:  Rafael Bitzur; Ronen Brenner; Elad Maor; Maayan Antebi; Tomer Ziv-Baran; Shlomo Segev; Yechezkel Sidi; Shaye Kivity
Journal:  Eur J Intern Med       Date:  2016-08-18       Impact factor: 4.487

7.  Metabolic syndrome and breast cancer prognosis.

Authors:  Franco Berrino; Anna Villarini; Adele Traina; Bernardo Bonanni; Salvatore Panico; Maria Piera Mano; Angelica Mercandino; Rocco Galasso; Maggiorino Barbero; Milena Simeoni; Maria Chiara Bassi; Elena Consolaro; Harriet Johansson; Maurizio Zarcone; Eleonora Bruno; Giuliana Gargano; Elisabetta Venturelli; Patrizia Pasanisi
Journal:  Breast Cancer Res Treat       Date:  2014-08-08       Impact factor: 4.872

Review 8.  Metabolic syndrome and postmenopausal breast cancer: systematic review and meta-analysis.

Authors:  Katherine Esposito; Paolo Chiodini; Annalisa Capuano; Giuseppe Bellastella; Maria Ida Maiorino; Concetta Rafaniello; Dario Giugliano
Journal:  Menopause       Date:  2013-12       Impact factor: 2.953

Review 9.  The link between the metabolic syndrome and cancer.

Authors:  Sandra Braun; Keren Bitton-Worms; Derek LeRoith
Journal:  Int J Biol Sci       Date:  2011-08-16       Impact factor: 6.580

Review 10.  Metabolic syndrome and risk of cancer: a systematic review and meta-analysis.

Authors:  Katherine Esposito; Paolo Chiodini; Annamaria Colao; Andrea Lenzi; Dario Giugliano
Journal:  Diabetes Care       Date:  2012-11       Impact factor: 19.112

View more
  1 in total

Review 1.  Common bean (Phaseolus vulgaris L.) α-amylase inhibitors as safe nutraceutical strategy against diabetes and obesity: An update review.

Authors:  Stefania Peddio; Alessandra Padiglia; Faustina B Cannea; Roberto Crnjar; Wissam Zam; Javad Sharifi-Rad; Antonio Rescigno; Paolo Zucca
Journal:  Phytother Res       Date:  2022-04-29       Impact factor: 6.388

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.